Top US health authorities recommended a "pause" in the use of Johnson & Johnson's COVID-19 vaccine "as a precaution" while they investigate whether it causes blood clots, a regulator said Tuesday, according to an AFP review.
The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are evaluating the "potential significance" of six reported cases of rare blood clots in patients who received the injection, the former tweeted.
"Until that process is complete, we recommend this pause," said the regulator, who reported that as of Monday, more than 6,8 million doses of Johnson & Johnson's vaccine had been administered in the United States.
“The CDC and FDA are reviewing data from 6 reported cases in the United States of a rare and severe type of blood clot produced in individuals after receiving the vaccine. At this time, these adverse events appear to be extremely rare, ”the FDA wrote on Twitter.
The agency said it is asking for this interruption to allow health care providers to obtain "the only treatment required against this type of blood clot."
CDC will convene an advisory committee Wednesday “to further review these cases and assess their potential significance. The FDA will review that analysis as it is also investigating these cases. "
The statement came days after the European Union's drug regulator said it is also reviewing possible cases of blood clots in people who received the Johnson & Johnson injection.